z-logo
open-access-imgOpen Access
Vancomycin in adult prescribing: is it time to move on from trough-based dosing in the UK?
Author(s) -
Francesca Heard,
Ashwini R. Sehgal
Publication year - 2021
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkab274
Subject(s) - dosing , vancomycin , medicine , nephrotoxicity , therapeutic drug monitoring , guideline , intensive care medicine , trough concentration , antibiotics , staphylococcus aureus , pharmacology , drug , toxicity , microbiology and biotechnology , biology , pathology , bacteria , genetics
Vancomycin remains a useful agent in the infection doctor’s toolkit, particularly for Staphylococcus aureus and MRSA infections. Therapeutic drug monitoring (TDM) is essential to maintain efficacy and avoid toxicity. Until recently, trough-based dosing has been the recommended method but in recent years the reliability of this has been questioned. The 2020 Infectious Diseases Society of America (IDSA) vancomycin guideline update has sent a clear message that trough-based dosing is not to be relied on, instead recommending dosing via 24 h AUC/MIC. The UK, however, has yet to follow suit in this, despite the wealth of evidence showing that trough-based dosing puts patients at higher risk of nephrotoxicity. Clearly, it is time to incorporate AUC/MIC-based dosing to utilize this effective antibiotic safely.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom